After more than a year of bitter legal jockeying, an attempt to begin breaking the nation's biggest courthouse logjam - lawsuits surrounding asbestos - faces a critical test on courtroom. The case is complicated by any standard: millions of potential plaintiffs, dozens of lawyers, 20 defendants and more than two decades of wrangling over damages for people suffering from asbestos exposure.
The proposal to pay an estimated 100,000 asbestos-related disease sufferers or their families about $ 1 billion over the next 10 years is even more complex with stiff opposition and allegations of misconduct.
Backers and detractors will state their positions in a fairness hearing here Tuesday before U.S. District Judge Lowell Reed.
Lawyers who negotiated the deal call it a model for a faster and better way to compensate asbestos disease victims whose needs have gone unmet in court. Opponents call it inadequate and the result of collusion between the Center for Claims Resolution, a group of 20 former asbestos makers, and two law firms: Greitzer & Locks of Philadelphia and Ness, Motley, Loadholt, Richardson & Poole of Charleston, S.C.
Under the deal, consideration for damages would be given to anyone who requests it, a vastly simpler arrangement than hiring an attorney and waiting years for a case to wind its way through the justice system, said John Aldock, a lawyer for the Center for Claims Resolution.
A nationwide asbestos resolution has proven elusive. More than 100,000 cases are lined up in state and federal courts. The litigation has cost U.S. companies an estimated $ 7 billion, some $ 4 billion of it going to lawyers.
Under the settlement, average payments range from $ 5,800 for non-malignant disorders, such as labored breathing, to $ 60,000 for mesothelioma, a terminal lung cancer. The amounts are based on historical averages, proponents said, with the neediest paid first.
Only those showing symptoms get money. Victims could request additional compensation if they develop more serious illnesses. The CCR doesn't include the biggest asbestos manufacturers, and settlement plaintiffs still could sue them.
Critics argue that in most cases plaintiffs will receive a fifth of what they could win in court. Because of docket gridlock, however, most states are hearing cases filed in the late 1980s. All federal lawsuits have been on hold since 1992.
Wages, the union leader, figures that 350,000 to 400,000 of his current and former union members were exposed to potentially deadly amounts of asbestos. Many, including himself, will not be covered by the settlement because they weren't exposed for long enough periods - at least 10 years for mesothelioma and 12 years for other ailments.
Overall, more than 27 million Americans are estimated to have job-related exposure to asbestos, a natural insulator used for decades in construction, and roughly 1 million targeted by cancer. Not all of those people were exposed to products made by the companies included in the CCR, however.
There also have been questions about whether people who don't want to join the settlement "class" were adequately informed. People who wanted to be excluded, remaining free to sue CCR companies, had to inform the court by Jan. 24.
The settlement, filed in January 1993, received preliminary approval in October by Judge Reed, who ruled that accusations of collusion between the two firms and the CCR were unfounded.
Philadelphia lawyer Ben Shein said the law firms didn't do enough to determine whether defendants could afford to pay without a settlement. The National Asbestos Victims Legal Action Organizing Committee estimates the CCR members have $ 53.6 billion in assets.
But backers said draining company assets has driven 17 former asbestos manufacturers into bankruptcy. Locks said the settlement requires insurers to pay when necessary, helping guarantee defendants solvency as cases mount.
About the Author
For the latest asbestosis information, including case studies, treatment, diagnosis and symptoms, see: Mesothelioma Info.
Saturday, May 12, 2007
Tuesday, May 8, 2007
Controversial Asbestos Settlement Heads to Court
After more than a year of bitter legal jockeying, an attempt to begin breaking the nation's biggest courthouse logjam - lawsuits surrounding asbestos - faces a critical test on courtroom. The case is complicated by any standard: millions of potential plaintiffs, dozens of lawyers, 20 defendants and more than two decades of wrangling over damages for people suffering from asbestos exposure.
The proposal to pay an estimated 100,000 asbestos-related disease sufferers or their families about $ 1 billion over the next 10 years is even more complex with stiff opposition and allegations of misconduct.
Backers and detractors will state their positions in a fairness hearing here Tuesday before U.S. District Judge Lowell Reed.
Lawyers who negotiated the deal call it a model for a faster and better way to compensate asbestos disease victims whose needs have gone unmet in court. Opponents call it inadequate and the result of collusion between the Center for Claims Resolution, a group of 20 former asbestos makers, and two law firms: Greitzer & Locks of Philadelphia and Ness, Motley, Loadholt, Richardson & Poole of Charleston, S.C.
Under the deal, consideration for damages would be given to anyone who requests it, a vastly simpler arrangement than hiring an attorney and waiting years for a case to wind its way through the justice system, said John Aldock, a lawyer for the Center for Claims Resolution.
A nationwide asbestos resolution has proven elusive. More than 100,000 cases are lined up in state and federal courts. The litigation has cost U.S. companies an estimated $ 7 billion, some $ 4 billion of it going to lawyers.
Under the settlement, average payments range from $ 5,800 for non-malignant disorders, such as labored breathing, to $ 60,000 for mesothelioma, a terminal lung cancer. The amounts are based on historical averages, proponents said, with the neediest paid first.
Only those showing symptoms get money. Victims could request additional compensation if they develop more serious illnesses. The CCR doesn't include the biggest asbestos manufacturers, and settlement plaintiffs still could sue them.
Critics argue that in most cases plaintiffs will receive a fifth of what they could win in court. Because of docket gridlock, however, most states are hearing cases filed in the late 1980s. All federal lawsuits have been on hold since 1992.
Wages, the union leader, figures that 350,000 to 400,000 of his current and former union members were exposed to potentially deadly amounts of asbestos. Many, including himself, will not be covered by the settlement because they weren't exposed for long enough periods - at least 10 years for mesothelioma and 12 years for other ailments.
Overall, more than 27 million Americans are estimated to have job-related exposure to asbestos, a natural insulator used for decades in construction, and roughly 1 million targeted by cancer. Not all of those people were exposed to products made by the companies included in the CCR, however.
There also have been questions about whether people who don't want to join the settlement "class" were adequately informed. People who wanted to be excluded, remaining free to sue CCR companies, had to inform the court by Jan. 24.
The settlement, filed in January 1993, received preliminary approval in October by Judge Reed, who ruled that accusations of collusion between the two firms and the CCR were unfounded.
Philadelphia lawyer Ben Shein said the law firms didn't do enough to determine whether defendants could afford to pay without a settlement. The National Asbestos Victims Legal Action Organizing Committee estimates the CCR members have $ 53.6 billion in assets.
But backers said draining company assets has driven 17 former asbestos manufacturers into bankruptcy. Locks said the settlement requires insurers to pay when necessary, helping guarantee defendants solvency as cases mount.
About the Author
For the latest asbestosis information, including case studies, treatment, diagnosis and symptoms, see: Mesothelioma Info.
The proposal to pay an estimated 100,000 asbestos-related disease sufferers or their families about $ 1 billion over the next 10 years is even more complex with stiff opposition and allegations of misconduct.
Backers and detractors will state their positions in a fairness hearing here Tuesday before U.S. District Judge Lowell Reed.
Lawyers who negotiated the deal call it a model for a faster and better way to compensate asbestos disease victims whose needs have gone unmet in court. Opponents call it inadequate and the result of collusion between the Center for Claims Resolution, a group of 20 former asbestos makers, and two law firms: Greitzer & Locks of Philadelphia and Ness, Motley, Loadholt, Richardson & Poole of Charleston, S.C.
Under the deal, consideration for damages would be given to anyone who requests it, a vastly simpler arrangement than hiring an attorney and waiting years for a case to wind its way through the justice system, said John Aldock, a lawyer for the Center for Claims Resolution.
A nationwide asbestos resolution has proven elusive. More than 100,000 cases are lined up in state and federal courts. The litigation has cost U.S. companies an estimated $ 7 billion, some $ 4 billion of it going to lawyers.
Under the settlement, average payments range from $ 5,800 for non-malignant disorders, such as labored breathing, to $ 60,000 for mesothelioma, a terminal lung cancer. The amounts are based on historical averages, proponents said, with the neediest paid first.
Only those showing symptoms get money. Victims could request additional compensation if they develop more serious illnesses. The CCR doesn't include the biggest asbestos manufacturers, and settlement plaintiffs still could sue them.
Critics argue that in most cases plaintiffs will receive a fifth of what they could win in court. Because of docket gridlock, however, most states are hearing cases filed in the late 1980s. All federal lawsuits have been on hold since 1992.
Wages, the union leader, figures that 350,000 to 400,000 of his current and former union members were exposed to potentially deadly amounts of asbestos. Many, including himself, will not be covered by the settlement because they weren't exposed for long enough periods - at least 10 years for mesothelioma and 12 years for other ailments.
Overall, more than 27 million Americans are estimated to have job-related exposure to asbestos, a natural insulator used for decades in construction, and roughly 1 million targeted by cancer. Not all of those people were exposed to products made by the companies included in the CCR, however.
There also have been questions about whether people who don't want to join the settlement "class" were adequately informed. People who wanted to be excluded, remaining free to sue CCR companies, had to inform the court by Jan. 24.
The settlement, filed in January 1993, received preliminary approval in October by Judge Reed, who ruled that accusations of collusion between the two firms and the CCR were unfounded.
Philadelphia lawyer Ben Shein said the law firms didn't do enough to determine whether defendants could afford to pay without a settlement. The National Asbestos Victims Legal Action Organizing Committee estimates the CCR members have $ 53.6 billion in assets.
But backers said draining company assets has driven 17 former asbestos manufacturers into bankruptcy. Locks said the settlement requires insurers to pay when necessary, helping guarantee defendants solvency as cases mount.
About the Author
For the latest asbestosis information, including case studies, treatment, diagnosis and symptoms, see: Mesothelioma Info.
Wednesday, May 2, 2007
Asbestos: Still a Carcinogen
Asbestos is an important cause of human illness. Clinical and epidemiologic studies have established incontrovertibly that asbestos causes cancer of the lung, malignant mesothelioma of the pleura and peritoneum, cancer of the larynx, and certain gastrointestinal cancers. Asbestos also causes asbestosis, a progressive fibrotic disease of the lungs. The risk of these diseases increases with cumulative exposure and also with the length of time since the first exposure
Asbestos is a generic term applied to a group of minerals, all of them fibrous. There are four commercially important forms: chrysotile, crocidolite, amosite, and anthophyllite. Chrysotile is the most important. It accounts for more than 95 percent of current world production. Nearly all asbestos used in North America has been chrysotile from the province of Quebec, Canada
All forms of asbestos are carcinogenic. All have been shown in clinical, epidemiologic, and laboratory studies to be fully capable of causing lung cancer, mesothelioma, and the full range of asbestos-related diseases. Although crocidolite appears to be two to four times more potent than chrysotile or amosite in its capacity to induce mesothelioma, all forms appear to be equally potent in their capacity to cause cancer of the lung.
New use of asbestos has almost completely ended in the United States and in most other developed nations as the result of government bans and market pressures. Those forces were stimulated by the landmark epidemiologic studies of Selikoff and colleagues6 and by the release of information on the carcinogenicity of asbestos that had previously been suppressed by the industry.7 By contrast, extensive and aggressive marketing of asbestos by Canada and other exporting nations continues in the developing world, where sales remain strong.
Asbestos is a generic term applied to a group of minerals, all of them fibrous. There are four commercially important forms: chrysotile, crocidolite, amosite, and anthophyllite. Chrysotile is the most important. It accounts for more than 95 percent of current world production. Nearly all asbestos used in North America has been chrysotile from the province of Quebec, Canada
All forms of asbestos are carcinogenic. All have been shown in clinical, epidemiologic, and laboratory studies to be fully capable of causing lung cancer, mesothelioma, and the full range of asbestos-related diseases. Although crocidolite appears to be two to four times more potent than chrysotile or amosite in its capacity to induce mesothelioma, all forms appear to be equally potent in their capacity to cause cancer of the lung.
New use of asbestos has almost completely ended in the United States and in most other developed nations as the result of government bans and market pressures. Those forces were stimulated by the landmark epidemiologic studies of Selikoff and colleagues6 and by the release of information on the carcinogenicity of asbestos that had previously been suppressed by the industry.7 By contrast, extensive and aggressive marketing of asbestos by Canada and other exporting nations continues in the developing world, where sales remain strong.
Monday, December 11, 2006
The Viciousness of Lung Cancer
Understanding The Viciousness of Lung Cancer by David Silva
Lung cancer is the result of malignant cells forming in the tissues of the lung, usually in the cells lining the air passages. The cells in our bodies are constantly dividing and reproducing. Usually, there's an orderly pattern to this reproduction as cells develop and specialize to meet particular needs. Occasionally, however, a cell becomes damaged. There's a mutation in its DNA, and rather than maturing and dying as is normal, it continues to reproduce unchecked. In essence, this is cancer - uncontrolled reproduction and growth of abnormal cells in the body.
Most lung cancers are believed to start in the epithelial lining of the lungs - the linings of the large and small airways that perform the task of extracting oxygen from the air. Because of this, lung cancer is sometimes called bronchogenic carcinoma - cancer arising from the bronchia. A smaller percentage of lung cancers begin in the pleura - the thin tissue sac that surrounds the lungs. These cancers are called mesothelioma. The most common form of mesothelioma is linked to asbestos exposure.
Cancer of the lungs is one of the deadliest forms of cancer. While it may take a period of years to develop, the cancer often goes undetected until late in the process. In addition, it tends to metastasize (migrate to other parts of the body) early, which leaves fewer opportunities to fight the mutated cells with surgery or radiation. Once the lung cancer does metastasize, it quickly spreads to the most vulnerable and important organs of the body, particularly the adrenal glands, the liver, the brain and the bones.
There are two primary forms of lung cancer - Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). Small Cell Lung Cancer is less common, though far more deadly. It's directly linked to cigarette smoking - less than 1% of SCLC is diagnosed in non-smokers. It's also extremely aggressive and fast-moving, metastasizing rapidly to other organs, and often undiscovered until it's already widespread.
Non-Small Cell Lung Cancer, on the other hand, is far more common, accounting for nearly 80% of all diagnosed lung cancers. There are three main types of non-small cell lung cancer, generally characterized by the size, shape, and chemical composition of the cells that form the cancer:
Squamous Cell Carcinoma (also referred to as Epidermoid Carcinoma): accounts for around 25% - 30% of all lung cancers, and is associated with a history of smoking. This cancer is nearly always found in the central chest area, near the bronchus.
Adenocarcinoma (also referred to as Bronchioloalveolar Carcinoma): accounts for around 40% of all lung cancers, and is found in the external region of the lung. Treatment for this form of lung cancer often leads to a more successful outcome than that of other lung cancers.
Large-Cell Undifferentiated Carcinoma: accounting for only 10% - 15% of lung cancers, this form may show up in any area of the lung. It tends to spread quickly, and often results in a poor prognosis.
It's also possible for lung cancer to be a combination of Non-Small Cell Lung Cancer types.
There are other, less common types of lung cancer. For instance, bronchial carcinoids are small tumors often found in people under 40 years of age. They tend to grow slowly, and be amenable to treatment. Carcinoid tumors account for approximately 5% of lung tumors. Some are non-cancerous. The others are generally slow-growing and can be successfully treated with surgery.
Finally, some cancers discovered in the lungs aren't lung cancers at all. Since the lungs are prone to metastatic cancers from other sites, it's not uncommon for tumors from other primary cancers to find their way to the lungs. When this occurs, the tumors are often discovered in the peripheral tissues of the lungs rather than in the central tissues.
Please note that the information provided in this article is for information purposes only. It should not be used during a medical emergency or for the diagnosis or treatment of lung cancer. Such situations should always involve the expertise of a physician or health care provider.
About the Author
David Silva is the webmaster for Lung Cancer Insights, a site dedicated to the dissemination of information about lung cancer, mesothelioma, non-small cell lung cancer, and their treatments.
Lung cancer is the result of malignant cells forming in the tissues of the lung, usually in the cells lining the air passages. The cells in our bodies are constantly dividing and reproducing. Usually, there's an orderly pattern to this reproduction as cells develop and specialize to meet particular needs. Occasionally, however, a cell becomes damaged. There's a mutation in its DNA, and rather than maturing and dying as is normal, it continues to reproduce unchecked. In essence, this is cancer - uncontrolled reproduction and growth of abnormal cells in the body.
Most lung cancers are believed to start in the epithelial lining of the lungs - the linings of the large and small airways that perform the task of extracting oxygen from the air. Because of this, lung cancer is sometimes called bronchogenic carcinoma - cancer arising from the bronchia. A smaller percentage of lung cancers begin in the pleura - the thin tissue sac that surrounds the lungs. These cancers are called mesothelioma. The most common form of mesothelioma is linked to asbestos exposure.
Cancer of the lungs is one of the deadliest forms of cancer. While it may take a period of years to develop, the cancer often goes undetected until late in the process. In addition, it tends to metastasize (migrate to other parts of the body) early, which leaves fewer opportunities to fight the mutated cells with surgery or radiation. Once the lung cancer does metastasize, it quickly spreads to the most vulnerable and important organs of the body, particularly the adrenal glands, the liver, the brain and the bones.
There are two primary forms of lung cancer - Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). Small Cell Lung Cancer is less common, though far more deadly. It's directly linked to cigarette smoking - less than 1% of SCLC is diagnosed in non-smokers. It's also extremely aggressive and fast-moving, metastasizing rapidly to other organs, and often undiscovered until it's already widespread.
Non-Small Cell Lung Cancer, on the other hand, is far more common, accounting for nearly 80% of all diagnosed lung cancers. There are three main types of non-small cell lung cancer, generally characterized by the size, shape, and chemical composition of the cells that form the cancer:
Squamous Cell Carcinoma (also referred to as Epidermoid Carcinoma): accounts for around 25% - 30% of all lung cancers, and is associated with a history of smoking. This cancer is nearly always found in the central chest area, near the bronchus.
Adenocarcinoma (also referred to as Bronchioloalveolar Carcinoma): accounts for around 40% of all lung cancers, and is found in the external region of the lung. Treatment for this form of lung cancer often leads to a more successful outcome than that of other lung cancers.
Large-Cell Undifferentiated Carcinoma: accounting for only 10% - 15% of lung cancers, this form may show up in any area of the lung. It tends to spread quickly, and often results in a poor prognosis.
It's also possible for lung cancer to be a combination of Non-Small Cell Lung Cancer types.
There are other, less common types of lung cancer. For instance, bronchial carcinoids are small tumors often found in people under 40 years of age. They tend to grow slowly, and be amenable to treatment. Carcinoid tumors account for approximately 5% of lung tumors. Some are non-cancerous. The others are generally slow-growing and can be successfully treated with surgery.
Finally, some cancers discovered in the lungs aren't lung cancers at all. Since the lungs are prone to metastatic cancers from other sites, it's not uncommon for tumors from other primary cancers to find their way to the lungs. When this occurs, the tumors are often discovered in the peripheral tissues of the lungs rather than in the central tissues.
Please note that the information provided in this article is for information purposes only. It should not be used during a medical emergency or for the diagnosis or treatment of lung cancer. Such situations should always involve the expertise of a physician or health care provider.
About the Author
David Silva is the webmaster for Lung Cancer Insights, a site dedicated to the dissemination of information about lung cancer, mesothelioma, non-small cell lung cancer, and their treatments.
Tuesday, December 5, 2006
Medical Procedures for a Mesothelioma Patient
Treatments and Medical Procedures for a Mesothelioma Patient by Gust A. Lenglet
Once a patient has been diagnosed with mesothelioma, both the doctor and the patient must then determine the best possible treatment. Mesothelioma prognosis, or the recovering factor for a patient, will vary based on several different characteristics:
1. Size of the mesothelioma
2. Whether or not the cancer is spreading
3. Where the mesothelioma is located
4. The patient's physical health condition and age
5. How the cells are portrayed under a microscope
Three Different Types of Mesothelioma Cells
1. Mixed Cell Type - This cell type is a mixture of the cancer cells and is normally labeled as an intermediate form of the cancer.
2. Epithelial Cell Type - These cells are the most treatable, and have the best prognosis.
3. Fibrosarcomatous Cell Type - This cell type is the worst type of mesothelioma, and has a negative prognosis.
How a Treatment is Selected
Treatments and procedures for mesothelioma are selected after considering the characteristics and cell types above. There are standard treatments, which have been tested on previous patient studies, and are most commonly used. There are also trials and/or experimental treatments that may be explored at the patient's or doctor's wishes.
Malignant Mesothelioma and Standard Treatments
The most common treatment of malignant mesothelioma is a surgery in which the doctor will remove part of the abdomen or chest lining and some tissue surrounding it. A lung may be removed or part of the diaphragm, based on how far the mesothelioma has spread. Removal of the lung is a procedure called "pneumonectomy." Radiation and/or chemotherapy are also a part of the standard treatments along with the surgery. Radiation kills off cancer cells using high-energy rays or x-rays. Chemotherapy kills cancer cells using drugs taken either by pill or needle injection. Each of these treatments will result in side effects, varying from one patient to the next.
Intraoperative Photodynamic Therapy
This is a type of treatment which utilizes light and drugs to kill the cancer cells during a surgical procedure. The goal of the surgery is to remove the cancer (as much as possible), and to shine alight on the pleura, killing additional cancer cells. Studies of this type of surgery are being performed on patients in the early stages of mesothelioma of the chest.
Clinical Tests
Occasionally a mesothelioma patient may be urged to participate in experimental treatment options, where the patient will be exposed to new ideas and procedures that are being developed. Oftentimes, traditional treatments will be combined with new tests to find more effective ways of fighting mesothelioma. These options are available for patients who may not be able to endure the standard treatments for health or physical reasons.
The earlier mesothelioma is detected in a patient, the better the prognosis. Each patient should be aware of all treatment options before making a decision, and also consult with a specialist to learn the best option for them.
About the Author
Gust A. Lenglet has been an accountant and financial advisor for many years. He is President and CEO of HBS Financial Group, Ltd. and offers online tax filing through his many web sites. He is also an accomplished author in the tax, legal, and education fields.
Once a patient has been diagnosed with mesothelioma, both the doctor and the patient must then determine the best possible treatment. Mesothelioma prognosis, or the recovering factor for a patient, will vary based on several different characteristics:
1. Size of the mesothelioma
2. Whether or not the cancer is spreading
3. Where the mesothelioma is located
4. The patient's physical health condition and age
5. How the cells are portrayed under a microscope
Three Different Types of Mesothelioma Cells
1. Mixed Cell Type - This cell type is a mixture of the cancer cells and is normally labeled as an intermediate form of the cancer.
2. Epithelial Cell Type - These cells are the most treatable, and have the best prognosis.
3. Fibrosarcomatous Cell Type - This cell type is the worst type of mesothelioma, and has a negative prognosis.
How a Treatment is Selected
Treatments and procedures for mesothelioma are selected after considering the characteristics and cell types above. There are standard treatments, which have been tested on previous patient studies, and are most commonly used. There are also trials and/or experimental treatments that may be explored at the patient's or doctor's wishes.
Malignant Mesothelioma and Standard Treatments
The most common treatment of malignant mesothelioma is a surgery in which the doctor will remove part of the abdomen or chest lining and some tissue surrounding it. A lung may be removed or part of the diaphragm, based on how far the mesothelioma has spread. Removal of the lung is a procedure called "pneumonectomy." Radiation and/or chemotherapy are also a part of the standard treatments along with the surgery. Radiation kills off cancer cells using high-energy rays or x-rays. Chemotherapy kills cancer cells using drugs taken either by pill or needle injection. Each of these treatments will result in side effects, varying from one patient to the next.
Intraoperative Photodynamic Therapy
This is a type of treatment which utilizes light and drugs to kill the cancer cells during a surgical procedure. The goal of the surgery is to remove the cancer (as much as possible), and to shine alight on the pleura, killing additional cancer cells. Studies of this type of surgery are being performed on patients in the early stages of mesothelioma of the chest.
Clinical Tests
Occasionally a mesothelioma patient may be urged to participate in experimental treatment options, where the patient will be exposed to new ideas and procedures that are being developed. Oftentimes, traditional treatments will be combined with new tests to find more effective ways of fighting mesothelioma. These options are available for patients who may not be able to endure the standard treatments for health or physical reasons.
The earlier mesothelioma is detected in a patient, the better the prognosis. Each patient should be aware of all treatment options before making a decision, and also consult with a specialist to learn the best option for them.
About the Author
Gust A. Lenglet has been an accountant and financial advisor for many years. He is President and CEO of HBS Financial Group, Ltd. and offers online tax filing through his many web sites. He is also an accomplished author in the tax, legal, and education fields.
Thursday, August 31, 2006
patterns of malignant pleural mesothelioma
Malignant pleural mesotheliomais known to mimic morphologically a number of diverse reactive and neoplastic conditions. We describe three unusual intraparenchymal growth patterns of malignant mesothelioma seen in a series of 200 malignant pleural mesotheliomas. The diagnostic pitfalls associated with these findings are described and their potential medico-legal implications are highlighted.
The study group comprised 200 malignant pleural mesotheliomas. In each case diagnosis was morphologically confirmed with ancillary immunohistochemistry using a broad panel of both mesothelial and epithelial markers. The patterns of intraparenchymal growth were documented and grouped as: direct subpleural; lymphangitic; and other. The 200 malignant pleural mesotheliomas comprised 118 epithelioid, 57 biphasic and 25 sarcomatoid, subtyped according to the WHO classification. Direct subpleural invasion was seen in 42 cases, lymphangitic spread in 27 cases. Other less well-defined intraparenchymal patterns included three sarcomatoid subtype malignant mesotheliomas exhibiting an intra-alveolar growth pattern mimicking epithelioid haemangioendothelioma. One epithelioid subtype malignant mesothelioma contained an intraparenchymal tumour nodule microscopically comprising lepidic spread of neoplastic cells over maintained alveolar structures mimicking bronchioloalveolar carcinoma. One epithelioid subtype malignant mesothelioma morphologically had areas in which alveoli were distended by discohesive epithelioid neoplastic cells with no interstitial invasion. The appearances mimicked desquamative interstitial pneumonia. Immunohistochemistry played an important role in the definitive diagnosis of each unusual parenchymal tumour deposit. In 126 malignant mesotheliomas no invasion of the subjacent lung parenchyma was identified.
An awareness of the unusual parenchymal growth pattern in malignant mesothelioma is important to prevent misdiagnosis of other entities. In the medico-legal setting, the presence of epithelioid haemangioendothelioma or bronchioloalveolar carcinoma (in the absence of asbestosis) may be deemed to impact upon the patient's anticipated life expectancy and thereby would decrease the compensation settlement.
The study group comprised 200 malignant pleural mesotheliomas. In each case diagnosis was morphologically confirmed with ancillary immunohistochemistry using a broad panel of both mesothelial and epithelial markers. The patterns of intraparenchymal growth were documented and grouped as: direct subpleural; lymphangitic; and other. The 200 malignant pleural mesotheliomas comprised 118 epithelioid, 57 biphasic and 25 sarcomatoid, subtyped according to the WHO classification. Direct subpleural invasion was seen in 42 cases, lymphangitic spread in 27 cases. Other less well-defined intraparenchymal patterns included three sarcomatoid subtype malignant mesotheliomas exhibiting an intra-alveolar growth pattern mimicking epithelioid haemangioendothelioma. One epithelioid subtype malignant mesothelioma contained an intraparenchymal tumour nodule microscopically comprising lepidic spread of neoplastic cells over maintained alveolar structures mimicking bronchioloalveolar carcinoma. One epithelioid subtype malignant mesothelioma morphologically had areas in which alveoli were distended by discohesive epithelioid neoplastic cells with no interstitial invasion. The appearances mimicked desquamative interstitial pneumonia. Immunohistochemistry played an important role in the definitive diagnosis of each unusual parenchymal tumour deposit. In 126 malignant mesotheliomas no invasion of the subjacent lung parenchyma was identified.
An awareness of the unusual parenchymal growth pattern in malignant mesothelioma is important to prevent misdiagnosis of other entities. In the medico-legal setting, the presence of epithelioid haemangioendothelioma or bronchioloalveolar carcinoma (in the absence of asbestosis) may be deemed to impact upon the patient's anticipated life expectancy and thereby would decrease the compensation settlement.
Saturday, August 26, 2006
Asbestos Lung Cancer Treatment
Mesothelioma is mainly caused due to contact with asbestos, which has zeolite. When inhaled, the asbestos fibers reach the pleural layer of our lungs and damages the mesothelial cells. When consumed, the asbestos fibers get to our abdominal cavity and cause peritoneal mesothelioma that can spread to the other parts of the body.
Mesothelioma (cancer of the mesothelium) is a disease in which cells of the mesothelium become abnormal and divide without control or order. They can invade and damage nearby tissues and organs. Cancer cells can also metastasize (spread) from their original site to other parts of the body. It is a rare disease caused as a result of malignant cancerous cells lining the patient's body cavities such as chest, abdominal region or the area surrounding the heart. This disease is very difficult to assess consistently due to the great variability in time before diagnosis and the rate of progression of malignant mesothelioma.
Even insignificant exposure to asbestos (commonly reported in such work environments as asbestos mills, mines, shipping yards, some older Navy ships or patients homes) is known to result in mesothelioma, which in many cases does not occur for decades after initial exposure to this cancer-causing substance. It is also known that family members of workers exposed to asbestos can contract this disease through exposure to the workers clothing. Smoking greatly increases the risk of contracting mesothelioma. Some of the earliest symptoms of mesothelioma can often be mistaken for less serious illness and are commonly overlooked. Some patients do not show any signs of sickness in the early stages of development of the disease. Most commonly the symptoms include dyspnea, pleuritic pain, lasting cough, fatigue, and weight loss. This disease is more common in men. Most cases of mesothelioma occur 30-45 years after initial exposure to asbestos. Once it develops, this cancer will continue to grow until it is treated. It is very important that the disease is diagnosed and treated as early as possible.
Working with asbestos is the major risk factor for mesothelioma. A history of asbestos exposure at work is reported in about 70 percent to 80 percent of all cases. However, mesothelioma has been reported in some individuals without any known exposure to asbestos. If tiny asbestos particles float in the air, especially during the manufacturing process, they may be inhaled or swallowed, and can cause serious health problems. In addition to mesothelioma, exposure to asbestos increases the risk of lung cancer, asbestosis (a noncancerous, chronic lung ailment), and other cancers, such as those of the larynx and kidney.
Mesothelioma is a malignant disease that can affect the lining of any internal organ. Most often the pleural lining of the lungs and/or the peritoneal lining of the organs in the abdominal cavity are affected. The plural lining of the lungs is affected when harmful amounts of asbestos are inhaled. When symptoms do develop they may include difficulty breathing, chest pain, and a chronic cough
The faster you consult the doctor and get specialized care the better your chances will be of dealing with this hazardous cancer. Please contact our doctor as soon as possible to get more information and cure the disease.
Many cancer treatment options are not very effective in treating mesothelioma. But at our center we provide you the treatment to reduce the disease and free you from the suffering from our specialist with the medication which are natural and no side effects.
Although reported incidence rates have increased in the past 20 years, mesothelioma is still a relatively rare cancer. Mesothelioma occurs more often in men than in women and risk increases with age, but this disease can appear in either men or women at any age.
Smoking does not appear to increase the risk of mesothelioma. However, the combination of smoking and asbestos exposure significantly increases a person's risk of developing cancer of the air passageways in the lung.
People who work with asbestos wear personal protective equipment to lower their risk of exposure.
Treatment for mesothelioma depends on the location of the cancer, the stage of the disease, and the patient's age and general health. Sometimes, these treatments are combined.
Mesothelioma (cancer of the mesothelium) is a disease in which cells of the mesothelium become abnormal and divide without control or order. They can invade and damage nearby tissues and organs. Cancer cells can also metastasize (spread) from their original site to other parts of the body. It is a rare disease caused as a result of malignant cancerous cells lining the patient's body cavities such as chest, abdominal region or the area surrounding the heart. This disease is very difficult to assess consistently due to the great variability in time before diagnosis and the rate of progression of malignant mesothelioma.
Even insignificant exposure to asbestos (commonly reported in such work environments as asbestos mills, mines, shipping yards, some older Navy ships or patients homes) is known to result in mesothelioma, which in many cases does not occur for decades after initial exposure to this cancer-causing substance. It is also known that family members of workers exposed to asbestos can contract this disease through exposure to the workers clothing. Smoking greatly increases the risk of contracting mesothelioma. Some of the earliest symptoms of mesothelioma can often be mistaken for less serious illness and are commonly overlooked. Some patients do not show any signs of sickness in the early stages of development of the disease. Most commonly the symptoms include dyspnea, pleuritic pain, lasting cough, fatigue, and weight loss. This disease is more common in men. Most cases of mesothelioma occur 30-45 years after initial exposure to asbestos. Once it develops, this cancer will continue to grow until it is treated. It is very important that the disease is diagnosed and treated as early as possible.
Working with asbestos is the major risk factor for mesothelioma. A history of asbestos exposure at work is reported in about 70 percent to 80 percent of all cases. However, mesothelioma has been reported in some individuals without any known exposure to asbestos. If tiny asbestos particles float in the air, especially during the manufacturing process, they may be inhaled or swallowed, and can cause serious health problems. In addition to mesothelioma, exposure to asbestos increases the risk of lung cancer, asbestosis (a noncancerous, chronic lung ailment), and other cancers, such as those of the larynx and kidney.
Mesothelioma is a malignant disease that can affect the lining of any internal organ. Most often the pleural lining of the lungs and/or the peritoneal lining of the organs in the abdominal cavity are affected. The plural lining of the lungs is affected when harmful amounts of asbestos are inhaled. When symptoms do develop they may include difficulty breathing, chest pain, and a chronic cough
The faster you consult the doctor and get specialized care the better your chances will be of dealing with this hazardous cancer. Please contact our doctor as soon as possible to get more information and cure the disease.
Many cancer treatment options are not very effective in treating mesothelioma. But at our center we provide you the treatment to reduce the disease and free you from the suffering from our specialist with the medication which are natural and no side effects.
Although reported incidence rates have increased in the past 20 years, mesothelioma is still a relatively rare cancer. Mesothelioma occurs more often in men than in women and risk increases with age, but this disease can appear in either men or women at any age.
Smoking does not appear to increase the risk of mesothelioma. However, the combination of smoking and asbestos exposure significantly increases a person's risk of developing cancer of the air passageways in the lung.
People who work with asbestos wear personal protective equipment to lower their risk of exposure.
Treatment for mesothelioma depends on the location of the cancer, the stage of the disease, and the patient's age and general health. Sometimes, these treatments are combined.
Subscribe to:
Posts (Atom)